| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Clinical Research Centers |
Division of Endocrinology, Departments of Medicine (J.C.L., J.B.T., P.A.F.) and Pediatrics (V.M.S., S.L.K., F.A.C., M.M.G.), University of California, San Francisco, California 94143
Address all correspondence to: Dr. Melvin Grumbach, Department of Pediatrics, University of California, San Francisco, California 94143-0434.
Women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency, especially those patients with the salt-losing form, have decreased fertility rates. Pregnancy experience in this population is limited. We report the pregnancy outcomes and serial measurements of maternal serum steroid levels in four women with classic 21-hydroxylase deficiency, three of whom were female pseudohermaphrodites with the salt-losing form. These glucocorticoid-treated women gave birth to four healthy female newborns with normal female external genitalia, none of whom were affected with 21-hydroxylase deficiency. In three women, circulating androgen levels increased during gestation, but remained within the normal range for pregnancy during glucocorticoid therapy. In the fourth patient, androgen levels were strikingly elevated during gestation despite increasing the dose of oral prednisone from 5 to 15 mg/day (two divided doses). Notwithstanding the high maternal serum concentration of androgens, however, placental aromatase activity was sufficient to prevent masculinization of the external genitalia of the female fetus and quite likely the fetal brain, consistent with the idea that placental aromatization of androgens to estrogens is the principal mechanism that protects the female fetus from the masculinizing effects of maternal hyperandrogenism. These four patients highlight key issues in the management of pregnancy in women with 21-hydroxylase deficiency, particularly the use of endocrine monitoring to assess adrenal androgen suppression in the mother, especially when the fetus is female. Recommendations for the management of pregnancy and delivery in these patients are discussed.
This article has been cited by other articles:
![]() |
K. Hagenfeldt, P.O. Janson, G. Holmdahl, H. Falhammar, H. Filipsson, L. Frisen, M. Thoren, and A. Nordenskjold Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency Hum. Reprod., July 1, 2008; 23(7): 1607 - 1613. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Merke Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 653 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Orans, D. G. Teotico, and M. R. Redinbo The Nuclear Xenobiotic Receptor Pregnane X Receptor: Recent Insights and New Challenges Mol. Endocrinol., December 1, 2005; 19(12): 2891 - 2900. [Abstract] [Full Text] [PDF] |
||||
![]() |
H B Holt, S Medbak, D Kirk, R Guirgis, I Hughes, M H Cummings, and D R Meeking Recurrent severe hyperandrogenism during pregnancy: a case report J. Clin. Pathol., April 1, 2005; 58(4): 439 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. NEW An Update of Congenital Adrenal Hyperplasia Ann. N.Y. Acad. Sci., December 1, 2004; 1038(1): 14 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. White and P. W. Speiser Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Endocr. Rev., June 1, 2000; 21(3): 245 - 291. [Abstract] [Full Text] |
||||
![]() |
Estrogen: Consequences and Implications of Human Mutations in Synthesis and Action J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4677 - 4694. [Abstract] [Full Text] |
||||
![]() |
K. Copeland Pregnancies and Offspring of Women with Congenital Adrenal Hyperplasia AAP Grand Rounds, August 1, 1999; 2(2): 19 - 20. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |